Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

The RNA-binding protein QKI controls alternative splicing in vascular cells, producing an effective model for therapy.

Caines R, Cochrane A, Kelaini S, Vila-Gonzalez M, Yang C, Eleftheriadou M, Moez A, Stitt AW, Zeng L, Grieve DJ, Margariti A.

J Cell Sci. 2019 Aug 15;132(16). pii: jcs230276. doi: 10.1242/jcs.230276.

PMID:
31331967
2.

NOX4 is a major regulator of cord blood-derived endothelial colony-forming cells which promotes postischaemic revascularisation.

O'Neill KM, Campbell DC, Edgar KS, Gill EK, Moez A, McLoughlin KJ, O'Neill CL, Dellett M, Hargey CJ, Abudalo RA, O'Hare M, Doyle P, Toh T, Khoo J, Wong J, McCrudden CM, Meloni M, Brunssen C, Morawietz H, Yoder MC, McDonald DM, Watson CJ, Stitt AW, Margariti A, Medina RJ, Grieve DJ.

Cardiovasc Res. 2019 Apr 1. pii: cvz090. doi: 10.1093/cvr/cvz090. [Epub ahead of print]

PMID:
30937452
3.

Special Issue: British Society for Cardiovascular Research : Introduction.

Grieve DJ.

Cardiovasc Drugs Ther. 2019 Apr;33(2):201. doi: 10.1007/s10557-019-06877-x. No abstract available.

PMID:
30895487
4.

Follistatin-Like 3 Enhances the Function of Endothelial Cells Derived from Pluripotent Stem Cells by Facilitating β-Catenin Nuclear Translocation Through Inhibition of Glycogen Synthase Kinase-3β Activity.

Kelaini S, Vilà-González M, Caines R, Campbell D, Eleftheriadou M, Tsifaki M, Magee C, Cochrane A, O'neill K, Yang C, Stitt AW, Zeng L, Grieve DJ, Margariti A.

Stem Cells. 2018 Jul;36(7):1033-1044. doi: 10.1002/stem.2820. Epub 2018 Apr 10.

5.

NADPH Oxidase-4 Driven Cardiac Macrophage Polarization Protects Against Myocardial Infarction-Induced Remodeling.

Mongue-Din H, Patel AS, Looi YH, Grieve DJ, Anilkumar N, Sirker A, Dong X, Brewer AC, Zhang M, Smith A, Shah AM.

JACC Basic Transl Sci. 2017 Dec 25;2(6):688-698. doi: 10.1016/j.jacbts.2017.06.006. eCollection 2017 Dec.

6.

Biochemical properties and biological actions of obestatin and its relevence in type 2 diabetes.

Green BD, Grieve DJ.

Peptides. 2018 Feb;100:249-259. doi: 10.1016/j.peptides.2017.12.006. Review.

PMID:
29412827
7.

New insights into cardiotoxicity caused by chemotherapeutic agents.

Grieve DJ, Davidson SM.

Br J Pharmacol. 2017 Nov;174(21):3675-3676. doi: 10.1111/bph.14025.

8.

Diabetic Nephropathy: a Tangled Web to Unweave.

Magee C, Grieve DJ, Watson CJ, Brazil DP.

Cardiovasc Drugs Ther. 2017 Dec;31(5-6):579-592. doi: 10.1007/s10557-017-6755-9. Review.

9.

Reactive oxygen species signalling in the diabetic heart: emerging prospect for therapeutic targeting.

Wilson AJ, Gill EK, Abudalo RA, Edgar KS, Watson CJ, Grieve DJ.

Heart. 2018 Feb;104(4):293-299. doi: 10.1136/heartjnl-2017-311448. Epub 2017 Sep 27. Review.

PMID:
28954833
10.

Are targeted therapies for diabetic cardiomyopathy on the horizon?

Tate M, Grieve DJ, Ritchie RH.

Clin Sci (Lond). 2017 May 1;131(10):897-915. doi: 10.1042/CS20160491. Review.

PMID:
28473471
11.

Signalling mechanisms underlying doxorubicin and Nox2 NADPH oxidase-induced cardiomyopathy: involvement of mitofusin-2.

McLaughlin D, Zhao Y, O'Neill KM, Edgar KS, Dunne PD, Kearney AM, Grieve DJ, McDermott BJ.

Br J Pharmacol. 2017 Nov;174(21):3677-3695. doi: 10.1111/bph.13773. Epub 2017 Apr 22.

12.

Treatment of lean and diet-induced obesity (DIO) mice with a novel stable obestatin analogue alters plasma metabolite levels as detected by untargeted LC-MS metabolomics.

Cowan E, Kumar P, Burch KJ, Grieve DJ, Green BD, Graham SF.

Metabolomics. 2016;12:124. doi: 10.1007/s11306-016-1063-0. Epub 2016 Jul 5.

13.

Obestatin as a key regulator of metabolism and cardiovascular function with emerging therapeutic potential for diabetes.

Cowan E, Burch KJ, Green BD, Grieve DJ.

Br J Pharmacol. 2016 Jul;173(14):2165-81. doi: 10.1111/bph.13502. Epub 2016 May 27. Review.

14.

Metabolically-inactive glucagon-like peptide-1(9-36)amide confers selective protective actions against post-myocardial infarction remodelling.

Robinson E, Tate M, Lockhart S, McPeake C, O'Neill KM, Edgar KS, Calderwood D, Green BD, McDermott BJ, Grieve DJ.

Cardiovasc Diabetol. 2016 Apr 14;15:65. doi: 10.1186/s12933-016-0386-5.

15.

Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages.

Tate M, Robinson E, Green BD, McDermott BJ, Grieve DJ.

Basic Res Cardiol. 2016 Jan;111(1):1. doi: 10.1007/s00395-015-0518-1. Epub 2015 Nov 23.

16.

Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix.

Robinson E, Cassidy RS, Tate M, Zhao Y, Lockhart S, Calderwood D, Church R, McGahon MK, Brazil DP, McDermott BJ, Green BD, Grieve DJ.

Basic Res Cardiol. 2015 Mar;110(2):20. doi: 10.1007/s00395-015-0476-7. Epub 2015 Mar 1.

17.

Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes.

Tate M, Chong A, Robinson E, Green BD, Grieve DJ.

Br J Pharmacol. 2015 Feb;172(3):721-36. doi: 10.1111/bph.12943. Epub 2014 Dec 1. Review.

18.

Endothelial NADPH oxidase-2 promotes interstitial cardiac fibrosis and diastolic dysfunction through proinflammatory effects and endothelial-mesenchymal transition.

Murdoch CE, Chaubey S, Zeng L, Yu B, Ivetic A, Walker SJ, Vanhoutte D, Heymans S, Grieve DJ, Cave AC, Brewer AC, Zhang M, Shah AM.

J Am Coll Cardiol. 2014 Jun 24;63(24):2734-41. doi: 10.1016/j.jacc.2014.02.572. Epub 2014 Mar 26.

19.

Adult cardiac fibroblast proliferation is modulated by calcium/calmodulin-dependent protein kinase II in normal and hypertrophied hearts.

Martin TP, Lawan A, Robinson E, Grieve DJ, Plevin R, Paul A, Currie S.

Pflugers Arch. 2014 Feb;466(2):319-30. doi: 10.1007/s00424-013-1326-9. Epub 2013 Jul 24.

PMID:
23881186
20.

Conformational change of mitochondrial complex I increases ROS sensitivity during ischemia.

Gorenkova N, Robinson E, Grieve DJ, Galkin A.

Antioxid Redox Signal. 2013 Nov 1;19(13):1459-68. doi: 10.1089/ars.2012.4698. Epub 2013 Mar 29.

21.

Surgical optimization and characterization of a minimally invasive aortic banding procedure to induce cardiac hypertrophy in mice.

Martin TP, Robinson E, Harvey AP, MacDonald M, Grieve DJ, Paul A, Currie S.

Exp Physiol. 2012 Jul;97(7):822-32. doi: 10.1113/expphysiol.2012.065573. Epub 2012 Mar 23.

22.

The gastrointestinal peptide obestatin induces vascular relaxation via specific activation of endothelium-dependent NO signalling.

Agnew AJ, Robinson E, McVicar CM, Harvey AP, Ali IH, Lindsay JE, McDonald DM, Green BD, Grieve DJ.

Br J Pharmacol. 2012 May;166(1):327-38. doi: 10.1111/j.1476-5381.2011.01761.x.

23.

In Vitro and In Vivo Effects of Natural Putative Secretagogues of Glucagon-Like Peptide-1 (GLP-1).

Rafferty EP, Wylie AR, Elliott CT, Chevallier OP, Grieve DJ, Green BD.

Sci Pharm. 2011 Jul-Sep;79(3):615-21. doi: 10.3797/scipharm.1104-16. Epub 2011 Jun 9.

24.

Investigating the effects of physiological bile acids on GLP-1 secretion and glucose tolerance in normal and GLP-1R(-/-) mice.

Rafferty EP, Wylie AR, Hand KH, Elliott CE, Grieve DJ, Green BD.

Biol Chem. 2011 Apr;392(6):539-46. doi: 10.1515/BC.2011.050. Epub 2011 Apr 27.

PMID:
21521075
25.

Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo.

Ray R, Murdoch CE, Wang M, Santos CX, Zhang M, Alom-Ruiz S, Anilkumar N, Ouattara A, Cave AC, Walker SJ, Grieve DJ, Charles RL, Eaton P, Brewer AC, Shah AM.

Arterioscler Thromb Vasc Biol. 2011 Jun;31(6):1368-76. doi: 10.1161/ATVBAHA.110.219238. Epub 2011 Mar 17.

PMID:
21415386
26.

Chronic treatment with a stable obestatin analog significantly alters plasma triglyceride levels but fails to influence food intake; fluid intake; body weight; or body composition in rats.

Agnew A, Calderwood D, Chevallier OP, Greer B, Grieve DJ, Green BD.

Peptides. 2011 Apr;32(4):755-62. doi: 10.1016/j.peptides.2010.12.005. Epub 2010 Dec 16.

PMID:
21167891
27.

NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis.

Zhang M, Brewer AC, Schröder K, Santos CX, Grieve DJ, Wang M, Anilkumar N, Yu B, Dong X, Walker SJ, Brandes RP, Shah AM.

Proc Natl Acad Sci U S A. 2010 Oct 19;107(42):18121-6. doi: 10.1073/pnas.1009700107. Epub 2010 Oct 4.

28.

Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy.

Zhao Y, McLaughlin D, Robinson E, Harvey AP, Hookham MB, Shah AM, McDermott BJ, Grieve DJ.

Cancer Res. 2010 Nov 15;70(22):9287-97. doi: 10.1158/0008-5472.CAN-10-2664. Epub 2010 Sep 30.

29.

Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

Grieve DJ, Cassidy RS, Green BD.

Br J Pharmacol. 2009 Aug;157(8):1340-51. doi: 10.1111/j.1476-5381.2009.00376.x. Review.

30.

Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease.

Robinson E, Grieve DJ.

Pharmacol Ther. 2009 Jun;122(3):246-63. doi: 10.1016/j.pharmthera.2009.03.003. Epub 2009 Mar 24. Review.

PMID:
19318113
31.

GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP.

Green BD, Hand KV, Dougan JE, McDonnell BM, Cassidy RS, Grieve DJ.

Arch Biochem Biophys. 2008 Oct 15;478(2):136-42. doi: 10.1016/j.abb.2008.08.001. Epub 2008 Aug 7.

PMID:
18708025
32.

Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction.

Looi YH, Grieve DJ, Siva A, Walker SJ, Anilkumar N, Cave AC, Marber M, Monaghan MJ, Shah AM.

Hypertension. 2008 Feb;51(2):319-25. doi: 10.1161/HYPERTENSIONAHA.107.101980. Epub 2008 Jan 7.

PMID:
18180403
33.

NADPH oxidases in cardiovascular health and disease.

Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S, Shah AM.

Antioxid Redox Signal. 2006 May-Jun;8(5-6):691-728. Review.

PMID:
16771662
34.

Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase.

Johar S, Cave AC, Narayanapanicker A, Grieve DJ, Shah AM.

FASEB J. 2006 Jul;20(9):1546-8. Epub 2006 May 23.

PMID:
16720735
35.

Leptin is an endothelial-independent vasodilator in humans with coronary artery disease: Evidence for tissue specificity of leptin resistance.

Momin AU, Melikian N, Shah AM, Grieve DJ, Wheatcroft SB, John L, El Gamel A, Desai JB, Nelson T, Driver C, Sherwood RA, Kearney MT.

Eur Heart J. 2006 Oct;27(19):2294-9. Epub 2006 Mar 16.

PMID:
16543250
36.

A national survey of infection control practice by New Zealand anaesthetists.

Ryan AJ, Webster CS, Merry AF, Grieve DJ.

Anaesth Intensive Care. 2006 Feb;34(1):68-74.

37.

Involvement of the nicotinamide adenosine dinucleotide phosphate oxidase isoform Nox2 in cardiac contractile dysfunction occurring in response to pressure overload.

Grieve DJ, Byrne JA, Siva A, Layland J, Johar S, Cave AC, Shah AM.

J Am Coll Cardiol. 2006 Feb 21;47(4):817-26. Epub 2006 Jan 26.

38.

NADPH oxidase and heart failure.

Murdoch CE, Grieve DJ, Cave AC, Looi YH, Shah AM.

Curr Opin Pharmacol. 2006 Apr;6(2):148-53. Epub 2006 Feb 17. Review.

PMID:
16483850
39.

Role of oxidative stress in cardiac remodelling after myocardial infarction.

Grieve DJ, Byrne JA, Cave AC, Shah AM.

Heart Lung Circ. 2004 Jun;13(2):132-8.

PMID:
16352183
40.

Protection against endotoxemia-induced contractile dysfunction in mice with cardiac-specific expression of slow skeletal troponin I.

Layland J, Cave AC, Warren C, Grieve DJ, Sparks E, Kentish JC, Solaro RJ, Shah AM.

FASEB J. 2005 Jul;19(9):1137-9. Epub 2005 Apr 26.

PMID:
15855227
41.

Analysis of ex vivo left ventricular pressure-volume relations in the isolated murine ejecting heart.

Grieve DJ, Cave AC, Byrne JA, Layland J, Shah AM.

Exp Physiol. 2004 Sep;89(5):573-82. Epub 2004 Jun 7.

42.

Essential role of troponin I in the positive inotropic response to isoprenaline in mouse hearts contracting auxotonically.

Layland J, Grieve DJ, Cave AC, Sparks E, Solaro RJ, Shah AM.

J Physiol. 2004 May 1;556(Pt 3):835-47. Epub 2004 Feb 13.

43.

Oxidative stress in heart failure. More than just damage.

Grieve DJ, Shah AM.

Eur Heart J. 2003 Dec;24(24):2161-3. No abstract available.

PMID:
14659766
44.

Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy.

Byrne JA, Grieve DJ, Bendall JK, Li JM, Gove C, Lambeth JD, Cave AC, Shah AM.

Circ Res. 2003 Oct 31;93(9):802-5. Epub 2003 Oct 9.

PMID:
14551238
45.

Vascular endothelial function and blood pressure homeostasis in mice overexpressing IGF binding protein-1.

Wheatcroft SB, Kearney MT, Shah AM, Grieve DJ, Williams IL, Miell JP, Crossey PA.

Diabetes. 2003 Aug;52(8):2075-82.

46.

Oxidative stress and heart failure.

Byrne JA, Grieve DJ, Cave AC, Shah AM.

Arch Mal Coeur Vaiss. 2003 Mar;96(3):214-21. Review.

PMID:
12722552
47.

Strain-dependent variation in vascular responses to nitric oxide in the isolated murine heart.

Bendall JK, Heymes C, Wright TJ, Wheatcroft S, Grieve DJ, Shah AM, Cave AC.

J Mol Cell Cardiol. 2002 Oct;34(10):1325-33.

PMID:
12392993
48.

Activation of NADPH oxidase during progression of cardiac hypertrophy to failure.

Li JM, Gall NP, Grieve DJ, Chen M, Shah AM.

Hypertension. 2002 Oct;40(4):477-84.

PMID:
12364350
49.

Impaired endothelial regulation of ventricular relaxation in cardiac hypertrophy: role of reactive oxygen species and NADPH oxidase.

MacCarthy PA, Grieve DJ, Li JM, Dunster C, Kelly FJ, Shah AM.

Circulation. 2001 Dec 11;104(24):2967-74.

PMID:
11739314
50.

Divergent biological actions of coronary endothelial nitric oxide during progression of cardiac hypertrophy.

Grieve DJ, MacCarthy PA, Gall NP, Cave AC, Shah AM.

Hypertension. 2001 Aug;38(2):267-73.

PMID:
11509488

Supplemental Content

Loading ...
Support Center